Indexed left ventricular mass by CMR demonstrated a strong association with adverse cardiovascular events (HR 0.75, p < 0.001) in patients with anthracycline-induced cardiomyopathy.
Observational (n=50)
Does left ventricular mass by cardiac magnetic resonance imaging predict adverse cardiovascular outcomes in patients treated with anthracycline-based chemotherapy?
Left ventricular mass measured by CMR is a strong predictor of adverse cardiovascular outcomes in patients receiving anthracycline chemotherapy.
Hazard Ratio: 0.75
valor p: p=<0.001
LV mass by CMR is a powerful predictor of adverse cardiovascular outcomes in patients treated with anthracyclines.
Neilan et al. (Wed,) conducted a observational in Stage B and C heart failure after anthracycline-based chemotherapy (n=50). Indexed left ventricular mass by CMR was evaluated on Adverse events (cardiovascular death and admission for heart failure) (hazard ratio: 0.75, p=<0.001). Indexed left ventricular mass by CMR demonstrated a strong association with adverse cardiovascular events (HR 0.75, p < 0.001) in patients with anthracycline-induced cardiomyopathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: